α-Isopropoxyaethyl-methylketon | 33667-32-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: α-Isopropoxyaethyl-methylketon
• 英文别名: 3-Propan-2-yloxybutan-2-one
• CAS: 33667-32-2
• 化学式: C₇H₁₄O₂
• 分子量: 130.187
• InChiKey: GYSOODZMSXFVBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• MOLECULAR PRECURSOR COMPOUNDS FOR ZINC-GROUP 13 MIXED OXIDE MATERIALS
  申请人：Precursor Energetics, Inc.

  公开号：US20150218190A1

  公开（公告）日：2015-08-06

  Molecular precursor compounds, processes and compositions for making Zn-Group 13 mixed oxide materials including IZO, GZO, AZO and BZO, by providing inks comprising a molecular precursor compound having the formula M A a Zn(OROR) 3a+2 , and printing or depositing the inks on a substrate. The printed or deposited ink films can be treated to convert the molecular precursor compounds to a material.

  分子前体化合物、制备Zn-Group 13混合氧化物材料（包括IZO、GZO、AZO和BZO）的过程和组合物，方法是提供包含具有公式M的分子前体化合物的油墨，在基底上印刷或沉积这些油墨。印刷或沉积的油墨膜可以经处理转化为材料。
• BOTTLEBRUSH COPOLYMERS AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20180094099A1

  公开（公告）日：2018-04-05

  Materials (e.g., particles, hydrogels) that provide extended release of one or more therapeutic agents are useful platforms for drug delivery. In part, the present invention relates to new triblock (ABC) bottlebrush copolymers which can be used in the formulation of particles and hydrogels for the extended release of therapeutic agents. In certain embodiments, the triblock bottlebrush copolymers, particles, and hydrogels described herein are thermally-responsive and gel at physiological temperature (e.g., upon administration to a subject), providing injectable and/or implantable gels which can be used for extended release drug delivery. The present invention also provides methods for extended release drug delivery, and methods of treating and/or preventing a disease or conditions in a subject, using the inventive copolymers, particles, and hydrogels. In addition, the present invention provides methods of preparing the triblock bottlebrush copolymers described herein.

  提供延长一个或多个治疗剂释放的材料（例如，颗粒、水凝胶）是药物传递的有用平台。在某种程度上，本发明涉及可用于制备颗粒和水凝胶以延长治疗剂释放的新三嵌段（ABC）瓶刷共聚物。在某些实施例中，本文描述的三嵌段瓶刷共聚物、颗粒和水凝胶对温度敏感，并在生理温度下凝胶（例如，在给予受试者后），提供可用于延长释放药物传递的可注射和/或可植入凝胶。本发明还提供了延长释放药物传递的方法，以及使用创新共聚物、颗粒和水凝胶治疗和/或预防受试者疾病或症状的方法。此外，本发明提供了制备本文描述的三嵌段瓶刷共聚物的方法。
• NOVEL ISOXAZOLE DRIVATIVE
  申请人：Ishikawa Makoto

  公开号：US20110065739A1

  公开（公告）日：2011-03-17

  Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an agonistic activity on GPR120 and is therefore useful for the treatment of diabetes, obesity or hyperlipemia. [In formula (I), the A represents a phenyl group which may be substituted by a lower alkoxy group or the like; the 13 represents a bivalent group produced by removing two hydrogen atoms from a benzene ring which may be substituted by a halogen atom or the like; X represents a lower alkylene group having 2 to 4 carbon atoms in its main chain or the like, wherein a carbon atom constituting the main chain may be substituted by an oxygen atom or the like; and Y represents a hydrogen atom or the like.]

  揭示了一种由式(I)表示的化合物或其药学上可接受的盐，该化合物对GPR120具有激动活性，因此对于治疗糖尿病、肥胖或高脂血症是有用的。【在式(I)中，A代表可能被低烷氧基或类似物取代的苯基；13代表通过从苯环中去除两个氢原子而产生的二价基团，该苯环可能被卤素原子或类似物取代；X代表具有2至4个碳原子的低烷基基团或类似物，其中构成主链的碳原子可能被氧原子或类似物取代；Y代表氢原子或类似物。】
• MOLECULAR PRECURSOR COMPOUNDS FOR INDIUM GALLIUM ZINC OXIDE MATERIALS
  申请人：TRANSTRON SOLUTIONS LLC

  公开号：EP3102541A1

  公开（公告）日：2016-12-14
• METHOD OF PREVENTING OR TREATING VIRAL INFECTION
  申请人：Department of Health and Human Services The United States of America, as Represented by the Secretary,

  公开号：US20130123344A1

  公开（公告）日：2013-05-16

  Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.